| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = -$80,939 ) |
| | 2026 | 2025 | ONCOARENDI THERAPEUTICS LLC | 93 SHENNECOSSETT RD | GROTON | CT | 06340-5115 | SOUTHEASTERN CT | USA | R43HL174237 | Myocardin-related transcription factor (MRTF) pathway modulators as a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF) | 000 | 2 | NIH | 1/12/2026 | -$80,939 |
|
| Issue Date FY: 2025 ( Subtotal = $66,458 ) |
| | 2025 | 2025 | ONCOARENDI THERAPEUTICS LLC | 93 SHENNECOSSETT RD | GROTON | CT | 06340-5115 | SOUTHEASTERN CT | USA | R43HL174237 | Myocardin-related transcription factor (MRTF) pathway modulators as a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF) | 000 | 2 | NIH | 4/7/2025 | $66,458 |
|
| Issue Date FY: 2024 ( Subtotal = $241,125 ) |
| | 2024 | 2024 | ONCOARENDI THERAPEUTICS LLC | 93 SHENNECOSSETT RD | GROTON | CT | 06340-5115 | SOUTHEASTERN CT | USA | R43HL174237 | Myocardin-related transcription factor (MRTF) pathway modulators as a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF) | 000 | 1 | NIH | 4/24/2024 | $241,125 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | ONCOARENDI THERAPEUTICS LLC | 125 DEVONSHIRE LN | MADISON | CT | 06443-8124 | SOUTH CENTRAL CT | USA | R43HL144350 | Potent oral chitotriosidase-1 inhibitors as a novel therapy for sarcoidosis | 000 | 1 | NIH | 7/30/2021 | $0 |
| | 2021 | 2018 | ONCOARENDI THERAPEUTICS LLC | 125 DEVONSHIRE LN | MADISON | CT | 06443-8124 | SOUTH CENTRAL CT | USA | R44HL132721 | Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma | 000 | 2 | NIH | 4/21/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2018 | ONCOARENDI THERAPEUTICS LLC | 125 DEVONSHIRE LN | MADISON | CT | 06443-8124 | SOUTH CENTRAL CT | USA | R44HL132721 | Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma | 000 | 2 | NIH | 5/7/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $237,200 ) |
| | 2019 | 2019 | ONCOARENDI THERAPEUTICS LLC | 125 DEVONSHIRE LN | MADISON | CT | 06443-8124 | SOUTH CENTRAL CT | USA | R43HL144350 | Potent oral chitotriosidase-1 inhibitors as a novel therapy for sarcoidosis | 000 | 1 | NIH | 4/9/2019 | $237,200 |
| | 2019 | 2018 | ONCOARENDI THERAPEUTICS LLC | 125 DEVONSHIRE LN | MADISON | CT | 06443-8124 | SOUTH CENTRAL CT | USA | R44HL132721 | Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma | 000 | 2 | NIH | 1/24/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,505,420 ) |
| | 2018 | 2018 | ONCOARENDI THERAPEUTICS LLC | 125 DEVONSHIRE LN | MADISON | CT | 06443-8124 | SOUTH CENTRAL CT | USA | R44HL132721 | Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma | 001 | 2 | NIH | 2/17/2018 | $1,505,420 |
| | 2018 | 2016 | ONCOARENDI THERAPEUTICS LLC | 125 DEVONSHIRE LN | MADISON | CT | 06443-8124 | SOUTH CENTRAL CT | USA | R44HL132721 | Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma | 000 | 1 | NIH | 12/13/2017 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2016 | ONCOARENDI THERAPEUTICS LLC | 125 DEVONSHIRE LN | MADISON | CT | 06443-8124 | SOUTH CENTRAL CT | USA | R44HL132721 | Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma | 001 | 1 | NIH | 9/11/2017 | $0 |
| | 2017 | 2016 | ONCOARENDI THERAPEUTICS LLC | 125 DEVONSHIRE LN | MADISON | CT | 06443-8124 | SOUTH CENTRAL CT | USA | R44HL132721 | Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma | 000 | 1 | NIH | 4/6/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $225,000 ) |
| | 2016 | 2016 | ONCOARENDI THERAPEUTICS LLC | 125 DEVONSHIRE LN | MADISON | CT | 06443-8124 | SOUTH CENTRAL CT | USA | R44HL132721 | Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma | 000 | 1 | NIH | 8/24/2016 | $225,000 |
|
|
